ObvioHealth, Mi-Helper Partner on Migraine Treatment Clinical Trial

ObvioHealth and Mi-Helper Inc. joining forces to conduct a decentralized clinical trial for a non-invasive neuromodulation device for treating migraines. The randomized controlled trial will be fully remote, enabling patients to capture data from home—where the device is intended to be used.
 
Mi-Helper developed its device to meet a significant unmet need for effective, targeted, and drug-free migraine pain management. Migraines impact 1 billion people worldwide, and severe headaches are among the top causes of U.S. emergency room outpatient visits. Additionally, in a recent study, 40% of migraine sufferers reported dissatisfaction with current treatments due to lack of efficacy, poor tolerability, and contraindications to common migraine-specific medications.
 
The small Mi-Helper device* delivers a controlled stream of conditioned air with a nebulized mist to mucosa membranes in the nose, providing relief from migraine-related pain and associated symptoms such as nausea and photosensitivity.
 
“We are working with the top headache neurologists in the world to inform our clinical studies,” Mi-Helper CEO Steve Schaefer said. “We are committed to delivering a paradigm shift for migraine treatment—fast, accessible, and affordable relief for this highly complex and debilitating neurological disease.” 
 
The Mi-Helper study features an adaptive design, beginning with the establishment of optimal dosing and culminating in a pivotal trial to determine therapeutic efficacy. The ObvioGo app will enable patients to remotely enroll, consent, and report relief of pain and other migraine symptoms as well as the use of rescue medications and any potential adverse events. ObvioHealth’s COACH (Clinical Oversight And Coordination Hub) team will remotely monitor patient compliance and safety in near real time.
 
“Mi-Helper and ObvioHealth are dedicated to inclusivity,” ObvioHealth CEO Ivan Jarry stated. “By designing a decentralized clinical trial without the need for physical site visits, we can recruit patients anywhere in the continental United States, including underserved communities. This will provide Mi-Helper with essential data on a real-world population in a real-world setting and should help to ensure that the device, when launched, can serve a broad population.”

The study is expected to begin recruiting this summer. 
 
Based in Baltimore, Md., Mi-Helper leverages patented processes to develop non-drug treatments for pain and mood disorders. Its at-home solutions are purpose-built for user-friendliness and accessibility, providing rapid relief without discomfort or side effects. 
The firm’s Mi-Helper device is for investigational use only and has not yet obtained U.S. Food and Drug Administration clearance.
 
ObvioHealth is an end-to-end virtual research organization (VRO), combining the clinical excellence of the best CROs with pioneering technology to optimize clinical trials at every stage and touchpoint. The company has been innovating decentralized study designs since 2017, leveraging ObvioGo—its proprietary DCT platform and app—as well as an in-house virtual site team and expert clinicians to improve patient engagement and deliver stronger evidence to trial sponsors.